Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men

American Journal of Clinical Nutrition

Volumn 100, Issue 2, 2014, Pages 514-523

  Steinert, Robert E ^a   Schirra, Joerg ^b   Meyer Gerspach, Anne C ^a   Kienle, Philipp ^a   Fischer, Heiko ^a   Schulte, Felix ^a   Goeke, Burkhard ^b   Beglinger, Christoph ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; EXENDIN (9-39); GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PEPTIDE FRAGMENT; PEPTIDE YY;

ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; APPETITE; BLOOD; CALORIC INTAKE; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG EFFECTS; FEEDING BEHAVIOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; UPREGULATION; VOMITING; YOUNG ADULT;

ADOLESCENT; ADULT; APPETITE; APPETITE DEPRESSANTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRINKING BEHAVIOR; ENERGY INTAKE; FEEDING BEHAVIOR; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PEPTIDE FRAGMENTS; PEPTIDE YY; POSTPRANDIAL PERIOD; RECEPTORS, GLUCAGON; UP-REGULATION; VOMITING; YOUNG ADULT;

EID: 84905399601     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.114.083246     Document Type: Article

References (45)

1. Punjabi M, Arnold M, Geary N, Langhans W, Pacheco-Lopez G. Peripheral glucagon-like peptide-1 (GLP-1) and satiation. Physiol Behav 2011;105:71-6.
2. Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab 2013;24:85-91.
3. Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond) 2013;37:1161-8.
4. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. J Clin Invest 1998;101:1421-30.
5. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Goke B. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006;55:243-51.
6. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999;48:86-93.
7. Wu T, Rayner CK, Young RL, Horowitz M. Gut motility and enteroendocrine secretion. Curr Opin Pharmacol 2013;13:928-34.
8. Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, Burgstad C, Jones KL, Chapman MJ, Rayner CK, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010;95:215-21.
9. Salehi M, Vahl TP, D'Alessio DA. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab 2008;93:4909-16.
10. Nicolaus M, Brödl J, Linke R, Woerle H-J, Göke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 2011;96:229-36.
11. Matzinger D, Gutzwiller JP, Drewe J, Orban A, Engel R, D'Amato M, Rovati L, Beglinger C. Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans. Am J Physiol 1999;277:R1718-24.
12. Castiglione KE, Read NW, French SJ. Food intake responses to upper gastrointestinal lipid infusions in humans. Physiol Behav 1998;64:141-5.
13. Steinert RE, Meyer-Gerspach AC, Beglinger C. The role of the stomach in the control of appetite and the secretion of satiation peptides. Am J Physiol Endocrinol Metab 2012;302:E666-73.
14. Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996;97:92-103.
15. Degen L, Oesch S, Matzinger D, Drewe J, Knupp M, Zimmerli F, Beglinger C. Effects of a preload on reduction of food intake by GLP-1 in healthy subjects. Digestion 2006;74:78-84.
16. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.
17. Beglinger S, Drewe J, Schirra J, Göke B, D'Amato M, Beglinger C. Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion. J Clin Endocrinol Metab 2010;95:879-86.
18. Matzinger D, Degen L, Drewe J, Meuli J, Duebendorfer R, Ruckstuhl N, D'Amato M, Rovati L, Beglinger C. The role of long chain fatty acids in regulating food intake and cholecystokinin release in humans. Gut 2000;46:688-93.
19. Feltrin KL, Little TJ, Meyer JH, Horowitz M, Smout AJPM, Wishart J, Pilichiewicz AN, Rades T, Chapman IM, Feinle-Bisset C. Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length. Am J Physiol Regul Integr Comp Physiol 2004;287:R524-33.
20. Schirra J, Morper M, Nicolaus M, Woerle HJ, Göke B. The efficacy of exendin (9-39) amide as a GLP-1 receptor antagonist in human. Gut 2008;57(suppl 2):A85.
21. Steinert RE, Poller B, Castelli M, Friedman K, Huber A, Drewe J, Beglinger C. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther 2009;86:644-50.
22. Blundell J, de Graaf C, Hulshof T, Jebb S, Livingstone B, Lluch A, Mela D, Salah S, Schuring E, van der Knaap H, et al. Appetite control: methodological aspects of the evaluation of foods. Obes Rev 2010;11:251-70.
23. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382-9.
24. Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44:81-6.
25. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541-4.
26. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973;84:488-95.
27. Smith GP, Gibbs J. Gut peptides and postprandial satiety. Fed Proc 1984;43:2889-92.
28. Geary N. Endocrine controls of eating: CCK, leptin, and ghrelin. Physiol Behav 2004;81:719-33.
29. Steinert RE, Feinle-Bisset C, Geary N, Beglinger C. Digestive physiology of the pig symposium: secretion of gastrointestinal hormones and eating control. J Anim Sci 2013;91:1963-73.
30. Beglinger C, Degen L. Gastrointestinal satiety signals in humans-physiologic roles for GLP-1 and PYY? Physiol Behav 2006;89:460-4.
31. Brennan IM, Feltrin KL, Horowitz M, Smout AJ, Meyer JH, Wishart J, Feinle-Bisset C. Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. Am J Physiol Regul Integr Comp Physiol 2005;288:R1477-85.
32. Rüttimann EB, Arnold M, Geary N, Langhans W. GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats. Physiol Behav 2010;100:291-6.
33. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009;150:1680-7.
34. Kim D-H, D'Alessio DA, Woods SC, Seeley RJ. The effects of GLP-1 infusion in the hepatic portal region on food intake. Regul Pept 2009;155:110-4.
35. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005;129:1430-6.
36. Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V. Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol 1992;262:R975-80.
37. Langhans W, Geary N. Overview of the physiological control of eating. Forum Nutr 2010;63:9-53.
38. Schultes B, Oltmanns KM, Kern W, Fehm HL, Born J, Peters A. Modulation of hunger by plasma glucose and metformin. J Clin Endocrinol Metab 2003;88:1133-41.
39. Kissileff HR, Carretta JC, Geliebter A, Pi-Sunyer FX. Cholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol Regul Integr Comp Physiol 2003;285:R992-8.
40. Muurahainen N, Kissileff HR, Derogatis AJ, Pi-Sunyer FX. Effects of cholecystokinin-octapeptide (CCK-8) on food intake and gastric emptying in man. Physiol Behav 1988;44:645-9.
41. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 2000;24:38-48.
42. Stubbs RJ, Hughes DA, Johnstone AM, Rowley E, Reid C, Elia M, Stratton R, Delargy H, King N, Blundell JE. The use of visual analogue scales to assess motivation to eat in human subjects: a review of their reliability and validity with an evaluation of new hand-held computerized systems for temporal tracking of appetite ratings. Br J Nutr 2000;84:405-15.
43. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997;273:E981-8.
44. Brennan IM, Otto B, Feltrin KL, Meyer JH, Horowitz M, Feinle-Bisset C. Intravenous CCK-8, but not GLP-1, suppresses ghrelin and stimulates PYY release in healthy men. Peptides 2007;28:607-11.
45. Drewe J, Gadient A, Rovati LC, Beglinger C. Role of circulating cholecystokinin in control of fat-induced inhibition of food intake in humans. Gastroenterology 1992;102:1654-9.